CHF 189.00

Cancer Immunotherapy at the Crossroads
How Tumors Evade Immunity and What Can Be Done

Inglese · Tascabile

Spedizione di solito entro 6 a 7 settimane

Descrizione

Ulteriori informazioni

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

Riassunto

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

Testo aggiuntivo

"...good reading for all those interested in oncological immunotherapy." -Cancer Forum


"State of the art and insightful...illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors." - Tumori

Relazione

"...good reading for all those interested in oncological immunotherapy." -Cancer Forum

"State of the art and insightful...illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors." - Tumori

Dettagli sul prodotto

Con la collaborazione di James H. Finke (Editore), Ronald M. Bukowski (Editore), Jame H Finke (Editore), M Bukowski (Editore), James H Finke (Editore), M Bukowski (Editore)
Editore Springer, Berlin
 
Contenuto Libro
Forma del prodotto Tascabile
Data pubblicazione 31.12.2013
Categoria Scienze naturali, medicina, informatica, tecnica > Medicina > Branche cliniche
 
EAN 9781468498448
ISBN 978-1-4684-9844-8
Numero di pagine 386
Illustrazioni XVII, 386 p.
Dimensioni (della confezione) 15.4 x 2.2 x 23.4 cm
Peso (della confezione) 589 g
 
Serie Current Clinical Oncology
Humana Press
Current Clinical Oncology
Categorie Tumor, C, Medicine, Transplantation, Oncology, Lymphoma, lymphocytes, Immunotherapy, renal cell carcinoma
 

Recensioni dei clienti

Per questo articolo non c'è ancora nessuna recensione. Scrivi la prima recensione e aiuta gli altri utenti a scegliere.

Scrivi una recensione

Top o flop? Scrivi la tua recensione.

Per i messaggi a CeDe.ch si prega di utilizzare il modulo di contatto.

I campi contrassegnati da * sono obbligatori.

Inviando questo modulo si accetta la nostra dichiarazione protezione dati.